
    
      This is an one-arm, phase II, single-center clinical study of Anlotinib in the treatment of
      recurrent small cell lung cancer, the objection is to exploring the efficacy and safety of
      Anlotinib in patients with relapsed small cell lung cancer.It is going to enroll 43 patients.
    
  